To find potential treatment for NSCLC with higher PEAK1 expression, we tested whether PD98059, an effective mitogen-activated protein kinase kinase (MEK) inhibitor, or AZD1480, a specific JAK2 inhibitor, could block PEAK1-induced EMT, cell migration and invasion in NSCLC. Here, JAK2 is linked to non-small cell lung carcinoma.